Skip to main content

Holmusk opens new office in Basel

| News

Holmusk opens new office in Basel


Holmusk has opened an office in Basel. The company from Singapore develops digital therapies on the basis of data analysis. Holmusk has placed a focus on the treatment of mental illnesses.

Nawal Roy, CEO of Holmusk (img: Holmusk)

Holmusk has recently moved into a new location at the Novartis Campus of the Switzerland Innovation Park Basel Area. The life sciences company develops data-driven digital therapies to treat a variety of disorders. Its focus is on mental and neurological illnesses, additionally Holmusk is active in the areas of cardiovascular and renal diseases, as well as diabetes.

The new office in Basel represents Holmusk’s seventh international office and second in Europe. According to Stefan Suter, Head of Holmusk Europe, staffing was a key consideration in the choice of Basel as a location: “In Basel we find multilingual, specialized talent from fresh graduates to seasoned professionals to be part of the data-driven revolution in healthcare”. In addition to current and future employees, the companies already located in Basel were also a significant pull factor for Holmusk. “Basel, with its large ecosystem of global leaders in life sciences offers multiple partnership opportunities and allows direct access to expand business into Germany or France”, explains Nawal Roy, CEO of Holmusk.

Holmusk is planning to build the world’s largest platform for what is known as real-world evidence (RWE), in which data from clinical practice is used to develop treatments. Holmusk has already been active in this area for five years, while the company also managed to successfully raise a total of 21.5 million US dollars in 2020 as part of a Series A financing round.

Switzerland Innovation Park Basel Area is operated by Basel Area Business & Innovation. The investment and innovation promotion agency also supported Holmusk during the process of establishing its business in the region.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.